What counter-ion should I expect on a QSC a GLP-1 receptor agonist lot?

What I am working with: QSC · a GLP-1 receptor agonist.

I would like help reading this properly rather than being told what conclusion to reach.

I have the full report including the method section, so I can quote specifics if that helps.

What would I need in addition before this supported a decision?

More usefully, a net-peptide-content figure already accounts for it, which is why net content is the number worth asking for.

Net peptide content — the fraction of gross mass that is the peptide itself — is the figure that folds water and counter-ion together and is what you should ask for if you ask for anything.

What each test answers

A supplier who reports both water and counter-ion has given you everything needed to reconcile the vial, and on this site that is a very short list.

Nothing here is medical advice, and research-use compounds are not approved for human use.

Count the basic residues and you can estimate the counter-ion load.

The honest answer is that most certificates are silent on it and that the number can be large enough to matter.

Worked reconciliation: a 10 mg vial at four per cent water and eight per cent trifluoroacetate contains 10.0 × 0.88 = 8.8 mg of peptide, a twelve per cent shortfall against label with a perfectly clean purity figure.

Quantification differs by ion: trifluoroacetate by ion chromatography or by fluorine nuclear magnetic resonance, acetate by ion chromatography or by capillary electrophoresis. Neither shows up on a UV chromatogram.

Net peptide content varies between lots as the process varies, so one figure does not characterise a supplier.

Trifluoroacetate unless a deliberate exchange was done. Ask which.

The short version: peptides are supplied as salts, the salt is real mass, and neither purity nor a chromatogram will tell you how much of it there is.

Acetate salts are produced by a deliberate ion exchange after purification. The exchange costs a processing step and is the reason acetate-form material is more expensive.

Peptides purified by reverse-phase chromatography with a trifluoroacetic acid mobile phase are isolated as trifluoroacetate salts. The trifluoroacetate content depends on the number of basic residues and can run from a few per cent to well over ten by mass on a heavily basic sequence.

Ion chromatography and fluorine NMR are the accepted quantitative methods for trifluoroacetate, and neither is a chromatographic purity method.

Water plus counter-ion is why gross mass and peptide mass differ.

Mechanically, this is the other half of the reconciliation problem, alongside water content.

The number of basic residues drives counter-ion load, because each protonated basic site pairs with one counter-ion. A sequence with several lysines and arginines carries proportionally more.

Trifluoroacetate effects in cell culture are documented and are the technical basis for salt exchange to acetate.

Ask for net peptide content. It folds water and counter-ion into one usable number.

Start with which counter-ion the process produced, because trifluoroacetate from reverse-phase purification and acetate from a salt exchange behave differently and are quantified differently.

Trifluoroacetate has documented biological effects at higher concentrations in cell culture, which is the technical reason acetate exchange exists rather than a marketing one.

The caveat is that a purity figure is completely blind to counter-ion content, and the two are routinely conflated.

Purity says nothing about counter-ion. They are unrelated measurements.